TY - JOUR
T1 - Muscle wasting in cancer cachexia
T2 - Clinical implications, diagnosis, and emerging treatment strategies
AU - Dodson, Shontelle
AU - Baracos, Vickie E.
AU - Jatoi, Aminah
AU - Evans, William J.
AU - Cella, David
AU - Dalton, James T.
AU - Steiner, Mitchell S.
PY - 2011/2/18
Y1 - 2011/2/18
N2 - Cancer cachexia is a complex metabolic condition characterized by loss of skeletal muscle. Common clinical manifestations include muscle wasting, anemia, reduced caloric intake, and altered immune function, which contribute to increased disability, fatigue, diminished quality of life, and reduced survival. The prevalence of cachexia and the impact of this disorder on the patient and family underscore the need for effective management strategies. Dietary supplementation and appetite stimulation alone are inadequate to reverse the underlying metabolic abnormalities of cancer cachexia and have limited long-term impact on patient quality of life and survival. Therapies that can increase muscle mass and physical performance may be a promising option; however, there are currently no drugs approved for the prevention or treatment of cancer cachexia. Several agents are in clinical development, including anabolic agents, such as selective androgen receptor modulators and drugs targeting inflammatory cytokines that promote skeletal muscle catabolism.
AB - Cancer cachexia is a complex metabolic condition characterized by loss of skeletal muscle. Common clinical manifestations include muscle wasting, anemia, reduced caloric intake, and altered immune function, which contribute to increased disability, fatigue, diminished quality of life, and reduced survival. The prevalence of cachexia and the impact of this disorder on the patient and family underscore the need for effective management strategies. Dietary supplementation and appetite stimulation alone are inadequate to reverse the underlying metabolic abnormalities of cancer cachexia and have limited long-term impact on patient quality of life and survival. Therapies that can increase muscle mass and physical performance may be a promising option; however, there are currently no drugs approved for the prevention or treatment of cancer cachexia. Several agents are in clinical development, including anabolic agents, such as selective androgen receptor modulators and drugs targeting inflammatory cytokines that promote skeletal muscle catabolism.
KW - anabolic
KW - body composition
KW - quality of life
KW - sarcopenia
KW - selective androgen receptor modulator
KW - skeletal muscle metabolism
UR - http://www.scopus.com/inward/record.url?scp=79551614788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79551614788&partnerID=8YFLogxK
U2 - 10.1146/annurev-med-061509-131248
DO - 10.1146/annurev-med-061509-131248
M3 - Article
C2 - 20731602
AN - SCOPUS:79551614788
SN - 0066-4219
VL - 62
SP - 265
EP - 279
JO - Annual Review of Medicine
JF - Annual Review of Medicine
ER -